Lys52
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Sumoylation Site Page: > Lys52  -  Myc (human)

Site Information
PSEDIWkkFELLPtP   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 40724404

In vivo Characterization
Methods used to characterize site in vivo:
electrophoretic mobility shift ( 2 ) , mass spectrometry ( 2 , 3 ) , mutation of modification site ( 2 ) , western blotting ( 2 )
Disease tissue studied:
bone cancer ( 2 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Treatments:
siRNA ( 2 )

Downstream Regulation
Effects of modification on Myc:
protein degradation ( 2 ) , ubiquitination ( 2 )
Effects of modification on biological processes:
transcription, inhibited ( 2 )

References 

1

Rabellino A, et al. (2016) PIAS1 Promotes Lymphomagenesis through MYC Upregulation. Cell Rep 15, 2266-78
27239040   Curated Info

2

González-Prieto R, et al. (2015) c-Myc is targeted to the proteasome for degradation in a SUMOylation-dependent manner, regulated by PIAS1, SENP7 and RNF4. Cell Cycle 14, 1859-72
25895136   Curated Info

3

Hendriks IA, et al. (2014) Uncovering global SUMOylation signaling networks in a site-specific manner. Nat Struct Mol Biol 21, 927-36
25218447   Curated Info